Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adalimumab + certolizumab pegol + etanercept + golimumab + infliximab
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
This is a combination listing of five tumor necrosis factor alpha (TNF-alpha) inhibitors: adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab. Each is a biologic disease-modifying antirheumatic drug (bDMARD) used primarily for the treatment of autoimmune diseases such as rheumatoid arthritis and ankylosing spondylitis. All five agents act by binding to TNF-alpha and inhibiting its interaction with TNF receptors, thereby reducing inflammation and immune-mediated tissue damage. While each drug has unique structural features—such as certolizumab being a PEGylated Fab' fragment lacking an Fc region—they share the same primary mechanism of action targeting TNF-alpha[1][2][9]. These drugs are not typically combined in clinical practice; rather, they are alternative monotherapies or used in combination with methotrexate or other DMARDs when indicated[3][4].
- Brand names
- Humira (adalimumab)Cimzia (certolizumab pegol)Enbrel (etanercept)Simponi (golimumab)Remicade (infliximab)
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))LTA (Lymphotoxin-alpha)
Beyond the preview
Go deeper on adalimumab + certolizumab pegol + etanercept + golimumab + infliximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adalimumab + certolizumab pegol + etanercept + golimumab + infliximab.